CG-200745 (Synonyms: CG-200745) |
Katalog-Nr.GC35668 |
CG-200745 (CG-200745) ist ein oral aktiver, potenter pan-HDAC-Inhibitor, der die HydroxamsÄureeinheit hat, um Zink am Boden der katalytischen Tasche zu binden. CG-200745 hemmt die Deacetylierung von Histon H3 und Tubulin. CG-200745 induziert die Akkumulation von p53, fÖrdert die p53-abhÄngige Transaktivierung und verstÄrkt die Expression der Proteine MDM2 und p21 (Waf1/Cip1). CG-200745 erhÖht die Empfindlichkeit von Gemcitabin-resistenten Zellen gegenÜber Gemcitabin und 5-Fluorouracil (5-FU; ). CG-200745 induziert Apoptose und hat Antitumorwirkungen.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 936221-33-9
Sample solution is provided at 25 µL, 10mM.
CG-200745 is a potent HDAC inhibitor, with IC50s of <3 μM for sensitive non-small cell lung cancer (NSCLC) cell lines. CG-200745 induces the accumulation of p53, promotes p53-dependent transactivation, and enhances the expression of proteins encoded by p53 target genes, MDM2 and p21 (Waf1/Cip1) in human prostate cancer cells[1]. CG-200745 attenuates phosphorylation of p38 MAPK in kidneys and it has a renoprotective effect by suppressing renal fibrosis and inflammation in a unilateral ureteral obstruction (UUO) mouse model[2]. HDAC p38 MAP kinase p53
CG-200745 (0-10 μM; 48 hours) reduces the Calu6 cells proliferation to 40% of untreated cells[1]. CG-200745 (3 μM; 1-24 hours) significantly increases Calu6 cells proportion in G2/M phase (69%)[1]. CG-200745 (0-10 μM; 1-24 hours) treatment with low concentration significantly increases the acetylation of histone H3 and H4 in Calu6 cells at various sites in a time-dependent manner up to 24 hours after treatment[1]. Cell Proliferation Assay[1] Cell Line: Calu6 cells
CG-200745 (p.o.; 30 mg/kg/day; for 7 days) attenuates oxidative stress, inflammatory cytokines, and adhesion molecules in UUO kidneys[2]. Animal Model: Male 8-week-old C57BL/6 J mice weighing 20~22 g of unilateral ureteral obstruction (UUO)[2]
[1]. Chun SM, et al. Epigenetic modulation with HDAC inhibitor CG200745 induces anti-proliferation in non-small cell lung cancer cells. PLoS One. 2015 Mar 17;10(3):e0119379. [2]. Choi HS, et al. Histone deacetylase inhibitor, CG200745 attenuates renal fibrosis in obstructive kidney disease. Sci Rep. 2018 Aug 1;8(1):11546.
Average Rating: 5
(Based on Reviews and 6 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *